Locus Cell Co., Ltd. (TPEX:6891)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
32.60
0.00 (0.00%)
Oct 9, 2025, 2:59 PM CST
Market Cap6.52B
Revenue (ttm)5.18M
Net Income (ttm)-164.24M
Shares Out200.00M
EPS (ttm)-0.83
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume260,105
Average Volume373,771
Open32.70
Previous Close32.60
Day's Range32.00 - 33.00
52-Week Range18.55 - 36.60
Beta0.69
RSI52.37
Earnings DateNov 13, 2025

About Locus Cell

Locus Cell Co., Ltd. focuses on contract development and manufacturing organization (CDMO) services for cell products in Taiwan and internationally. It offers tissue engineering CDMO services for adipose-derived stem cells, nerve cells, chondrocytes, fibroblasts, epithelial cells, 3D printing cell products, and other cell products; and regenerative medical product CDMO services, such as CAR-T, CAR-NK, iPSC, MSC/ADSC, and other cell types. The company is based in New Taipei City, Taiwan. [Read more]

Industry Biotechnology
Sector Healthcare
CEO Yu-Hsiang Chang
Employees 53
Stock Exchange Taipei Exchange
Ticker Symbol 6891
Full Company Profile

Financial Performance

In 2024, Locus Cell's revenue was 2.36 million, an increase of 480.30% compared to the previous year's 406,000. Losses were -113.02 million, 16.6% more than in 2023.

Financial Statements

News

There is no news available yet.